Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs Moderna, Inc. (MRNA) Price & Performance

Aehr Test SystemsTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Aehr Test Systems vs Moderna, Inc. — how do they compare? Aehr Test Systems trades at $132.31 (market cap $3.82B), while Moderna, Inc. trades at $63.54 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 6.3× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

AEHRMRNA
Market Cap
$3.82B$24.18B
Sector
TechnologyHealth
52-Week High
$117.18$81.80
52-Week Low
$17.38$22.36
Enterprise Value
$3.72B$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aehr Test Systems

AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.

Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA